Skip to main content

Treatment Landscape and Clinical Management of HER2-Positive mBC

Rapid Reactions
HER2-Positive mBC
Videos — July 5, 2022
Neil M. Iyengar, MD
Associate Attending
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
New York, NY
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, discusses his perspectives on the current treatment landscape and clinical management of HER2-positive mBC.

Related Items

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
By Hope S. Rugo, MD
Videos
Rapid Reactions
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
By Sara M. Tolaney, MD, MPH
Videos
Rapid Reactions
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
By Hope S. Rugo, MD
Videos
Rapid Reactions
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
By Sara M. Tolaney, MD, MPH
Videos
Rapid Reactions